New developments in the treatment of functional dyspepsia

Drugs

Volumn 63, Issue 9, 2003, Pages 869-892

  Stanghellini, Vincenzo ^a,c   De Ponti, Fabrizio ^a   De Giorgio, Roberto ^a   Barbara, Giovanni ^a   Tosetti, Cesare ^b   Corinaldesi, Roberto ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b National Health Service   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

8,9 ANHYDRO N ETHYLNORERYTHROMYCIN A 6,9 HEMIACETAL; ALEMCINAL; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIDEPRESSANT AGENT; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CISAPRIDE; DOMPERIDONE; DOPAMINE RECEPTOR BLOCKING AGENT; ERYTHROMYCIN; GASTROINTESTINAL AGENT; KAPPA OPIATE RECEPTOR AGONIST; METOCLOPRAMIDE; MITEMCINAL; MOTILIN; MOTILIN RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEPADUTANT; NOLPITANTIUM; PROKINETIC AGENT; PROTON PUMP INHIBITOR; PRUCALOPRIDE; PURINERGIC RECEPTOR BLOCKING AGENT; SAREDUTANT; SEROTONIN 3 AGONIST; SEROTONIN 4 AGONIST; SODIUM CHANNEL BLOCKING AGENT; SULPIRIDE; TACHYKININ RECEPTOR ANTAGONIST; TAK 637; TEGASEROD; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINOCICEPTION; CLINICAL FEATURE; CLINICAL TRIAL; DYSPEPSIA; GASTROINTESTINAL MOTILITY; HELICOBACTER PYLORI; HUMAN; HYPERSENSITIVITY; PATHOPHYSIOLOGY; REVIEW; STOMACH ACID SECRETION; TREATMENT OUTCOME; TREATMENT PLANNING;

DYSPEPSIA; GASTRIC ACID; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; HELICOBACTER PYLORI; HUMANS;

HELICOBACTER; HELICOBACTER PYLORI;

EID: 0038222635     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363090-00003     Document Type: Review

References (180)

1. Talley NJ, Stanghellini V, Heading RC, et al. Functional gastroduodenal disorders. Gut 1999; 45 Suppl. II: 37-42
2. Knill-Jones RP. Geographical differences in the prevalence of dyspepsia. Scand J Gastroenterol Suppl 1991; 182: 17-24
3. Penston JG, Pounder RE. A survey of dyspepsia in Great Britain. Aliment Pharmacol Ther 1996; 10: 83-9
4. Stanghellini V. Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999; 231: 20-8
5. Enck P, Dubois D, Marquis P. Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999; 231: 48-54
6. Talley NJ, Colin-Jones D, Koch KL, et al. Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterol Int 1991; 4: 145-60
7. Carlsson R, Dent J, Bolling-Sternevald E, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998; 33: 1023-9
8. Veldhuyzen van Zanten SJ, Flook N, Chiba N, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori: Canadian Dyspepsia Working Group. CMAJ 2000; 162 Suppl. 12: S3-S23
9. Stanghellini V, Tosetti C, De Giorgio R, et al. Functional dyspepsia: not all the roads lead to Rome. Dig Liver Dis 2002; 34: 316-8
10. Hungin AP, Rubin GP, O'Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 1999; 49: 451-3
11. Veldhuyzen van Zanten SJ, Talley NJ, Bytzer P, et al. Design of treatment trials for functional gastrointestinal disorders. Gut 1999; 45 Suppl. 2: 69-77
12. Stanghellini V, Tosetti C, Paternico A, et al. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 1996; 110: 1036-42
13. Whitaker MJ, Brun J, Carelli F. Controversy and consensus in the management of upper gastrointestinal disease in primary care: The International Gastro Primary Care Group. Int J Clin Pract 1997; 51: 239-43
14. Stanghellini V, Barbara G, De Giorgio R, et al. Helicobacter pylori, mucosal inflammation and symptom perception: new insights into an old hypothesis. Aliment Pharmacol Ther 2001; 15 Suppl. 1: 28-32
15. Son HJ, Rhee PL, Kim JJ, et al. Hypersensitivity to acid in ulcer-like functional dyspepsia. Korean J Intern Med 1997; 12: 188-92
16. George AA, Tsuchiyose M, Dooley CP. Sensitivity of the gastric mucosa to acid and duodenal contents in patients with nonulcer dyspepsia. Gastroenterology 1991; 101: 3-6
17. Tucci A, Corinaldesi R, Stanghellini V, et al. Helicobacter pylori infection and gastric function in patients with chronic idiopathic dyspepsia. Gastroenterology 1992; 103: 768-74
18. El-Omar E, Penman I, Ardill JE, et al. A substantial proportion of non-ulcer dyspepsia patients have the same abnormality of acid secretion as duodenal ulcer patients. Gut 1995; 36: 534-8
19. Talley NJ, Meineche-Schmidt V, Pare P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the BOND and OPERA studies). Aliment Pharmacol Ther 1998; 12: 1055-65
20. Farup PG, Hovde O, Torp R, et al. Patients with functional dyspepsia responding to omeprazole have a characteristic gastro-oesophageal reflux pattern. Scand J Gastroenterol 1999; 34: 575-9
21. Mehta AJ, De Caestecker JS, Camm AJ, et al. Sensitization to painful distention and abnormal sensory perception in the esophagus. Gastroenterology 1995; 108: 311-9
22. Coffin B, Azpiroz F, Guarner F, et al. Selective gastric hypersensitivity and reflex hyporeactivity in functional dyspepsia. Gastroenterology 1994; 107: 1345-51
23. Talley NJ. Dyspepsia: how to manage and how to treat? Aliment Pharmacol Ther 2002; 16 Suppl. 4: 95-104
24. Nyren O. Functional dyspepsia: bye-bye to PPIs. Gut 2002; 51: 464-5
25. Talley NJ. Dyspepsia management in the millennium: the death of test and treat? Gastroenterology 2002; 122: 1521-5
26. Veldhuyzen van Zanten SJ, Talley NJ, Blum AL, et al. Combined analysis of the ORCHID and OCAY studies: does eradication of Helicobacter pylori lead to sustained improvement in functional dyspepsia symptoms? Gut 2002; 50 Suppl. 4: 26-30
27. Talley NJ, Lauritsen K. The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies. Gut 2002; 50 Suppl. 4: 36-41
28. Soo S, Moayyedi P. Pharmacological interventions for non-ulcer dyspepsia. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 3. Oxford: Update Software, 2002
29. Blum AL, Arnold R, Stoke M, et al. Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group. Gut 2000; 47: 473-80
30. Wong WM, Wong BC, Hung WK, et al. Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut 2002; 51: 502-6
31. Stanghellini V, Ghidini C, Maccarini MR, et al. Fasting and postprandial gastrointestinal motility in ulcer and non-ulcer dyspepsia. Gut 1992; 33: 184-90
32. Malagelada JR, Stanghellini V. Manometric evaluation of functional upper gut symptoms. Gastroenterology 1985; 88: 1223-31
33. Troncon LE, Thompson DG, Ahluwalia NK, et al. Relations between upper abdominal symptoms and gastric distension abnormalities in dysmotility like functional dyspepsia and after vagotomy. Gut 1995; 37: 17-22
34. Tack J, Piessevaux H, Coulie B, et al. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998; 115: 1346-52
35. Pinto D, Tosetti C, Stanghellini V, et al. Ultrasonographic evaluation of gastric antral distension induced by a water load test in health subjects and patients with functional dispepsia [abstract]. Gastroenterology 2001; 120 Suppl. 1: A237
36. Villanova N, Azpiroz F, Malagelada JR. Gastrogastric reflexes regulating gastric tone and their relationship to perception. Am J Physiol 1997; 273: G464-9
37. Azpiroz F, Malagelada JR. Isobaric intestinal distension in humans: sensorial relay and reflex gastric relaxation. Am J Physiol 1990; 258: G202-7
38. Thumshirn M, Camilleri M, Choi MG, et al. Modulation of gastric sensory and motor functions by nitrergic and alpha2-adrenergic agents in humans. Gastroenterology 1999; 116: 573-85
39. Kuo B, Camilleri M, Burton D, et al. Effects of 5-HT3 antagonism on postprandial gastric volume and symptoms in humans. Aliment Pharmacol Ther 2002; 16: 225-33
40. Thumshirn M, Camilleri M, Saslow SB, et al. Gastric accommodation in non-ulcer dyspepsia and the roles of Helicobacter pylori infection and vagal function. Gut 1999; 44: 55-64
41. Mearin F, de Ribot X, Balboa A, et al. Does Helicobacter pylori infection increase gastric sensitivity in functional dyspepsia? Gut 1995; 37: 47-51
42. Mearin F, Cucala M, Azpiroz F, et al. The origin of symptoms on the brain-gut axis in functional dyspepsia. Gastroenterology 1991; 101: 999-1006
43. Mertz H, Fullerton S, Naliboff B, et al. Symptoms and visceral perception in severe functional and organic dyspepsia. Gut 1998; 42: 814-22
44. Samsom M, Verhagen MA, vanBerge Henegouwen GP, et al. Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. Gastroenterology 1999; 116: 515-20
45. Tack J, Piessevaux H, Coulie B, et al. Role of visceral hypersensitivity in patients with functional dyspepsia [abstract]. Gastroenterology 1998; 114: G1232
46. Tack J, Coulie B, Piessevaux H, et al. Postprandial gastric tone determines the sensitivity to postprandial distension in functional dyspepsia [abstract]. Neurogastroenterol Motil 1998; 10: 102
47. Holtmann G, Goebell H, Talley NJ. Functional dyspepsia and irritable bowel syndrome: is there a common pathophysiological basis? Am J Gastroenterol 1997; 92: 954-9
48. Trimble KC, Farouk R, Pryde A, et al. Heightened visceral sensation in functional gastrointestinal disease is not site-specific: evidence for a generalized disorder of gut sensitivity. Dig Dis Sci 1995; 40: 1607-13
49. Stanghellini V, Malagelada JR, Zinsmeister AR, et al. Stress-induced gastroduodenal motor disturbances in humans: possible humoral mechanisms. Gastroenterology 1983; 85: 83-91
50. Bennett EJ, Piesse C, Palmer K, et al. Functional gastrointestinal disorders: psychological, social, and somatic features. Gut 1998; 42: 414-20
51. Talley NJ, Boyce P, Jones M. Dyspepsia and health care seeking in a community: how important are psychological factors? Dig Dis Sci 1998; 43: 1016-22
52. Lemann M, Dederding JP, Flourie B, et al. Abnormal perception of visceral pain in response to gastric distension in chronic idiopathic dyspepsia: the irritable stomach syndrome. Dig Dis Sci 1991; 36: 1249-54
53. Talley NJ, Fett SL, Zinsmeister AR, et al. Gastrointestinal tract symptoms and self-reported abuse: a population-based study. Gastroenterology 1994; 107: 1040-9
54. Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355: 1035-40
55. Talley NJ, Haque M, Wyeth JW, et al. Development of a new dyspepsia impact scale: the Nepean Dyspepsia Index. Aliment Pharmacol Ther 1999; 13: 225-35
56. Heading RC, Wager E, Tooley PJ. Reliability of symptom assessment in dyspepsia. Eur J Gastroenterol Hepatol 1997; 9: 779-81
57. Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407-15
58. Veldhuyzen van Zanten SJ, Cleary C, Talley NJ, et al. Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol 1996; 91: 660-73
59. Kellow JE, Cowan H, Shuter B, et al. Efficacy of cisapride therapy in functional dyspepsia. Aliment Pharmacol Ther 1995; 9: 153-60
60. Distrutti E, Fiorucci S, Hauer SK, et al. Effect of acute and chronic levosulpiride administration on gastric tone and perception in functional dyspepsia. Aliment Pharmacol Ther 2002; 16: 613-22
61. Manes G, Dominguez-Munoz JE, Leodolter A, et al. Effect of cisapride on gastric sensitivity to distension, gastric compliance and duodeno-gastric reflexes in healthy humans. Dig Liver Dis 2001; 33: 407-13
62. Tack J, Broeckaert D, Coulie B, et al. The influence of cisapride on gastric tone and the perception of gastric distension. Aliment Pharmacol Ther 1998; 12: 761-6
63. Cipolla G, Sacco S, Crema F, et al. Gastric motor effects of triptans: open questions and future perspectives. Pharmacol Res 2001; 43: 205-10
64. Tack J, Coulie B, Wilmer A, et al. Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. Gut 2000; 46: 468-73
65. Tack J, Peeters T. What comes after macrolides and other motilin stimulants? Gut 2001; 49: 317-8
66. Holzer P, Holzer-Petsche U. Tachykinin receptors in the gut: physiological and pathological implications. Curr Opin Pharmacol 2001; 1: 583-90
67. Laird JM, Olivar T, Lopez-Garcia JA, et al. Responses of rat spinal neurons to distension of inflamed colon: role of tachykinin NK2 receptors. Neuropharmacology 2001; 40: 696-701
68. Read NW, Abithol JL, Bardhan KD, et al. Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia. Gut 1997; 41: 664-8
69. Junien JL, Riviere P. Review article: the hypersensitive gut: peripheral kappa agonists as a new pharmacological approach. Aliment Pharmacol Ther 1995; 9: 117-26
70. Viramontes BE, Malcolm A, Camilleri M, et al. Effects of an alpha(2)-adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans. Am J Physiol 2001; 281: G1468-76
71. Chizh BA, Headley PM, Tzschentke TM. NMDA receptor antagonists as analgesics: focus on the NR2B subtype. Trends Pharmacol Sci 2001; 22: 636-42
72. Feinle C, Meier O, Otto B, et al. Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Gut 2001; 48: 347-55
73. McQuay HJ, Moore RA. Antidepressants and chronic pain. BMJ 1997; 314: 763-4
74. Laird JM, Carter AJ, Grauert M, et al. Analgesic activity of a novel use-dependent sodium channel blocker, crobenetine, in mono-arthritic rats. Br J Pharmacol 2001; 134: 1742-8
75. Bielefeldt K, Ozaki N, Gebhart GF. Experimental ulcers alter voltage-sensitive sodium currents in rat gastric sensory neurons. Gastroenterology 2002; 122: 394-405
76. Bielefeldt K, Ozaki N, Gebhart GF. Mild gastritis alters voltage-sensitive sodium currents in gastric sensory neurons in rats. Gastroenterology 2002; 122: 752-61
77. Yiangou Y, Facer P, Baecker PA, et al. ATP-gated ion channel P2X(3) is increased in human inflammatory bowel disease. Neurogastroenterol Motil 2001; 13: 365-9
78. Burnstock G. Purine-mediated signalling in pain and visceral perception. Trends Pharmacol Sci 2001; 22: 182-8
79. Chizh BA, Illes P. P2X receptors and nociception. Pharmacol Rev 2001; 53: 553-68
80. Yiangou Y, Facer P, Dyer NH, et al. Vanilloid receptor 1 immunoreactivity in inflamed human bowel. Lancet 2001; 357: 1338-9
81. De Ponti F, Malagelada JR. Functional gut disorders: from motility to sensitivity disorders: a review of current and investigational drugs for their management. Pharmacol Ther 1998; 80: 49-88
82. Allescher HD, Bockenhoff A, Knapp G, et al. Treatment of non-ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies. Scand J Gastroenterol 2001; 36: 934-41
83. Cutts TF, Abell TL, Karas JG, et al. Symptom improvement from prokinetic therapy corresponds to improved quality of life in patients with severe dyspepsia. Dig Dis Sci 1996; 41: 1369-78
84. Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, et al. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001; 96: 689-96
85. Briejer MR, Akkermans LM, Schuurkes JA. Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol Rev 1995; 47: 631-51
86. Willems JL, Buylaert WA, Lefebvre RA, et al. Neuronal dopamine receptors on autonomic ganglia and sympathetic nerves and dopamine receptors in the gastrointestinal system. Pharmacol Rev 1985; 37: 165-216
87. Valenzuela JE. Dopamine as a possible neurotransmitter in gastric relaxation. Gastroenterology 1976; 71: 1019-22
88. Lanfranchi GA, Marzio L, Cortini C, et al. Motor effect of dopamine on human sigmoid colon: evidence for specific receptors. Am J Dig Dis 1978; 23: 257-63
89. Lanfranchi GA, Bazzocchi G, Fois F, et al. Effect of domperidone and dopamine on colonic motor activity in patients with the irritable bowel syndrome. Eur J Clin Pharmacol 1985; 29: 307-10
90. Marzio L, Neri M, Di Giammarco AM, et al. Dopamine-induced migrating myoelectrical complex-like activity in human duodenum. Dig Dis Sci 1986; 31: 349-54
91. Wiley J, Owyang C. Dopaminergic modulation of rectosigmoid motility: action of domperidone. J Pharmacol Exp Ther 1987; 242: 548-51
92. Marzio L, Neri M, Pieramico O, et al. Dopamine interrupts gastrointestinal fed motility pattern in humans: effect on motilin and somatostatin blood levels. Dig Dis Sci 1990; 35: 327-32
93. Mansi C, Borro P, Giacomini M, et al. Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis. Aliment Pharmacol Ther 2000; 14: 561-9
94. Arienti V, Corazza GR, Sorge M, et al. The effects of levosulpiride on gastric and gall-bladder emptying in functional dyspepsia. Aliment Pharmacol Ther 1994; 8: 631-8
95. Corazza GR, Biagi F, Albano O, et al. Levosulpiride in functional dyspepsia: a multicentric, double-blind, controlled trial. Ital J Gastroenterol 1996; 28: 317-23
96. Song CW, Chun HJ, Kim CD, et al. Effects of levosulpiride in patients with functional dyspepsia accompanied by delayed gastric emptying. Korean J Intern Med 1998; 13: 15-21
97. Schuurkes JAJ, Meulemans AL, Obertop H, et al. 5-HT4 receptors on the human stomach [abstract]. J Gastroint Motil 1991; 3: 199
98. Sakurai-Yamashita Y, Takada K, Takemura K, et al. Ability of mosapride to bind to 5-HT4 receptor in the human stomach. Jpn J Pharmacol 1999; 79: 493-6
99. Pillans PI, Wood SM. Cisapride increases micturition frequency. J Clin Gastroenterol 1994; 19: 336-8
100. Tonini M, Messori E, Franceschetti GP, et al. Characterization of the 5-HT receptor potentiating neuromuscular cholinergic transmission in strips of human isolated detrusor muscle. Br J Pharmacol 1994; 113: 1-2
101. Tonini M, De Ponti F, Di Nucci A, et al. Review article: cardiac adverse effects of gastrointestinal prokinetics. Aliment Pharmacol Ther 1999; 13: 1585-91
102. Fraser R, Horowitz M, Maddox A, et al. Dual effects of cisapride on gastric emptying and antropyloroduodenal motility. Am J Physiol 1993; 264: G195-201
103. Fraser RJ, Horowitz M, Maddox AF, et al. Postprandial antropyloroduodenal motility and gastric emptying in gastroparesis: effects of cisapride. Gut 1994; 35: 172-8
104. Malbert CH, Serthelon JP, Dent J. Changes in antroduodenal resistance induced by Cisapride in conscious dogs. Am J Physiol 1992: 263: G202-8
105. Holtmann G, Gschossmann J, Karaus M, et al. Randomised double-blind comparison of simethicone with cisapride in functional dyspepsia. Aliment Pharmacol Ther 1999; 13: 1459-65
106. Chen JD, Ke MY, Lin XM, et al. Cisapride provides symptomatic relief in functional dyspepsia associated with gastric myoelectrical abnormality. Aliment Pharmacol Ther 2000; 14: 1041-7
107. Wiseman LR, Faulds D. Cisapride: an updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994; 47: 116-52
108. Scott LJ, Perry, CM. Tegaserod. Drugs 1999; 58: 491-6
109. Camilleri M. Review article: tegaserod. Aliment Pharmacol Ther 2001; 15: 277-89
110. Poen AC, Felt-Bersma RJ, Van Dongen PA, et al. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther 1999; 13: 1493-7
111. Camilleri M, McKinzie S, Burton D, et al. Prucalopride accelerates small bowel and colonic transit in patients with chronic functional constipation (FC) or constipation-predominant irritable bowel syndrome (C-IBS) [abstract]. Gastroenterology 2000; 118 Suppl. 2: A845
112. De Ponti F, Tonini M. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs 2001; 61: 317-32
113. Kamm MA. The complexity of drug development for irritable bowel syndrome. Aliment Pharmacol Ther 2002; 16: 343-51
114. Peeters TL. Erythromycin and other macrolides as prokinetic agents. Gastroenterology 1993; 105: 1886-99
115. Itoh Z. Motilin and clinical application. Peptides 1997; 18: 593-608
116. Itoh Z, Suzuki T, Nakaya M, et al. Structure-activity relation among macrolide antibiotics in initiation of interdigestive migrating contractions in the canine gastrointestinal tract. Am J Physiol 1985; 248: G320-5
117. Clark MJ, Wright T, Bertrand PP, et al. Erythromycin derivatives ABT 229 and GM 611 act on motilin receptors in the rabbit duodenum. Clin Exp Pharmacol Physiol 1999; 26: 242-5
118. Siani MA, Skillman AG, Carreras CW, et al. Development and screening of a polyketide virtual library for drug leads against a motilide pharmacophore. J Mol Graph Model 2000; 18: 497-40
119. Costa A, De Ponti F, Gibelli G, et al. In vivo characterization of the colonic prokinetic effect of erythromycin in the rabbit. Pharmacology 1997; 54: 64-75
120. Depoortere I, Peeters TL, Vantrappen G. Motilin receptors of the rabbit colon. Peptides 1991; 12: 89-94
121. Coulie B, Tack J, Peeters T, et al. Involvement of two different pathways in the motor effects of erythromycin on the gastric antrum in humans. Gut 1998; 43: 395-400
122. Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin: preliminary studies. N Engl J Med 1990; 322: 1028-31
123. Bruley des Varannes S, Parys V, Ropert A, et al. Erythromycin enhances fasting and postprandial proximal gastric tone in humans. Gastroenterology 1995; 109: 32-9
124. Demedts I, Tack J, Coulie B, et al. Role of fundic tone in meal-induced satiety in man [abstract]. Gastroenterology 1997; 112: A720
125. Piessevaux H, Tack J, Coulie B, et al. Influence of erythromycin on the perception of gastric distension [abstract]. Gastroenterology 1997; 112: A806
126. Talley NJ, Verlinden M, Snape W, et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2000; 14: 1653-61
127. Camilleri M. Motilin agonists and dyspepsia: throwing out the baby with the bath water. Gut 2002; 51: 612-3
128. Talley N, Verlinden M. Authors' reply. Gut 2002; 51: 612-3
129. Camilleri M, Coulie B, Tack JF. Visceral hypersensitivity: facts, speculations, and challenges. Gut 2001; 48: 125-31
130. Kirkup AJ, Brunsden AM, Grundy D. Receptors and transmission in the brain-gut axis: potential for novel therapies: I, receptors on visceral afferents. Am J Physiol 2001; 280: G787-94
131. Tack J, Caenepeel P, Fischler B, et al. Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology 2001; 121: 526-35
132. Gershon MD. Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999; 13 Suppl. 2: 15-30
133. Moss HE, Sanger GJ. The effects of granisetron, ICS 205-930 and ondansetron on the visceral pain reflex induced by duodenal distension. Br J Pharmacol 1990; 100: 497-501
134. Miura M, Lawson DC, Clary EM, et al. Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist. Dig Dis Sci 1999; 44: 20-4
135. Delvaux M, Louvel D, Mamet JP, et al. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998; 12: 849-55
136. Prior A, Read NW. Reduction of rectal sensitivity and postprandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome. Alim Pharmacol Ther 1993; 7: 175-80
137. Goldberg PA, Kamm MA, Setti-Carraro P, et al. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion 1996; 57: 478-83
138. Feinle C, Read NW. Ondansetron reduces nausea induced by gastroduodenal stimulation without changing gastric motility. Am J Physiol 1996; 261: G591-7
139. Banner SE, Sanger GJ. Differences between 5-HT3 receptor antagonists in modulation of visceral hypersensitivity. Br J Pharmacol 1995; 114: 558-62
140. Gunput MD. Review article: clinical pharmacology of alosetron. Aliment Pharmacol Ther 1999; 13 Suppl. 2: 70-6
141. Humphrey PP, Bountra C, Clayton N, et al. Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1999; 13 Suppl. 2: 31-8
142. Balfour JA, Goa KL, Perry CM. Alosetron. Drugs 2000; 59: 511-8
143. Kozlowski CM, Green A, Grundy D, et al. The 5-HT3 receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut 2000; 46: 474-80
144. Zerbib F, Bruley des Verannes S, Oriola RC, et al. Alosetron does not affect the visceral perception of gastric distension in healthy subjects. Aliment Pharmacol Ther 1994; 8: 403-7
145. Thumshirn M, Coulie B, Camilleri M, et al. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2000; 14: 869-78
146. Talley NJ, Van Zanten SV, Saez LR, et al. A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Ther 2001; 15: 525-37
147. Tonini M, De Ponti F. Serotonin modulation of gastrointestinal motility. In: Gaginella TS, Galligan JJ, editors. Serotonin and gastrointestinal function. Boca Raton (FL): CRC Press, 1995: 53-84
148. Buchheit KH, Costall B, Engel G, et al. 5-Hydroxytryptamine receptor antagonism by metoclopramide and ICS 205-930 in the guinea-pig leads to enhancement of contractions of stomach muscle strips induced by electrical field stimulation and facilitation of gastric emptying in vivo. J Pharm Pharmacol 1985; 37: 664-7
149. Costall B, Gunning SJ, Naylor RJ, et al. The effect of GR38032F, novel 5-HT3-receptor antagonist on gastric emptying in the guinea-pig. Br J Pharmacol 1987; 91: 263-4
150. Schiavone A, Volonte M, Micheletti R. The gastrointestinal motor effect of benzamide derivatives is unrelated to 5-HT3 receptor blockade. Eur J Pharmacol 1990; 187: 323-9
151. Akkermans LM, Vos A, Hoekstra A, et al. Effect of ICS 205-930 (a specific 5-HT3 receptor antagonist) on gastric emptying of a solid meal in normal subjects. Gut 1988; 29: 1249-52
152. Nielsen OH, Hvid-Jacobsen K, Lund P, et al. Gastric emptying and subjective symptoms of nausea: lack of effects of a 5-hydroxytryptamine-3 antagonist ondansetron on gastric emptying in patients with gastric stasis syndrome. Digestion 1990; 46: 89-96
153. Stacher G, Bergmann H, Granser-Vacariu GV, et al. Lack of systematic effects of the 5-hydroxytryptamine 3 receptor antagonist ICS 205-930 on gastric emptying and antral motor activity in patients with primary anorexia nervosa. Br J Clin Pharmacol 1991; 32: 685-9
154. Eeckhout C, Gregory P, David S. 5-HT3 antagonists prevent intraduodenal lipid induced slowing of gastric emptying in dogs [abtract]. Gastroenterology 1994; 106: A492
155. Houghton LA, Fowler P, Keene ON, et al. Effect of sumatriptan, a new selective 5HT1-like agonist, on liquid gastric emptying in man. Aliment Pharmacol Ther 1992; 6: 685-91
156. Coulie B, Tack J, Maes B, et al. Sumatriptan, a selective 5-HT1 receptor agonist, induces a lag phase for gastric emptying of liquids in humans. Am J Physiol 1997; 272: G902-8
157. Boeckxstaens GE, Hirsch DP, Kuiken SD, et al. The proximal stomach and postprandial symptoms in functional dyspeptics. Am J Gastroenterol 2002; 97: 40-8
158. Coulie B, Tack J, Sifrim D, et al. Role of nitric oxide in fasting gastric fundus tone and in 5-HT1 receptor-mediated relaxation of gastric fundus. Am J Physiol 1999; 276: G373-7
159. De Ponti F, Crema F, Nardelli G, et al. Blockade by the selective 5-HT1B/D receptor antagonist GR127935 of the effect of sumatriptan on canine gastric compliance [abstract]. Neurogastroenterol Motil 2000; 12: 383
160. Meulemans AL, Elsen LF, de Ridder WJA, et al. Effects of sumatriptan on the guinea-pig isolated stomach [abstract]. Neurogastroenterol Motil 1996; 8: A183
161. Crema F, Nardelli G, Moro E, et al. Enhanced gastric accommodation by antimigraine triptans: role of 5-HT1B/D receptors [abstract]. Pharmacol Res 2001; 43 Suppl. A: 113
162. Coulie B, Tack J, Janssen J. Influence of buspirone-induced fundus relaxation on the perception of gastric distention in man [abstract]. Gastroenterology 1997; 112: A715
163. Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997; 112: 2120-37
164. Jackson JL, O'Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000; 108: 65-72
165. Mertz H, Fass R, Kodner A, et al. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998; 93: 160-5
166. Gorard DA, Libby GW, Farthing MJ. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8: 159-66
167. Gorard DA, Libby GW, Farthing MJ. Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Dig Dis Sci 1995; 40: 86-95
168. Peghini PL, Katz PO, Castell DO. Imipramine decreases oesophageal pain perception in human male volunteers. Gut 1998; 42: 807-13
169. Onghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain 1992; 49: 205-19
170. Pacher P, Ungvari Z, Nanasi PP, et al. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects: is there any? Curr Med Chem 1999; 6: 469-80
171. Altar CA. Neurotrophins and depression. Trends Pharmacol Sci 1999; 20: 59-61
172. Coulie B, Szarka LA, Camilleri M, et al. Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology 2000; 119: 41-50
173. Delvaux M. Pharmacology and clinical experience with fedotozine. Expert Opin Investig Drugs 2001; 10: 97-110
174. Coffin B, Bouhassira D, Chollet R, et al. Effect of the kappa agonist fedotozine on perception of gastric distension in healthy humans. Aliment Pharmacol Ther 1996; 10: 919-25
175. Fraitag B, Homerin M, Hecketsweiler P. Double-blind dose-response multicenter comparison of fedotozine and placebo in treatment of nonulcer dyspepsia. Dig Dis Sci 1994; 39: 1072-7
176. May B, Kohler S, Schneider B. Efficacy and tolerability of a fixed combination of peppermint oil and caraway oil in patients suffering from functional dyspepsia. Aliment Pharmacol Ther 2000; 14: 1671-7
177. Bortolotti M, Coccia G, Grossi G, et al. The treatment of functional dyspepsia with red pepper. Aliment Pharmacol Ther 2002; 16: 1075-82
178. Thompson Coon J, Ernst E. Systematic review: herbal medicinal products for non-ulcer dyspepsia. Aliment Pharmacol Ther 2002; 16: 1689-99
179. Bueno L, Fioramonti J, Garcia-Villar R. Pathobiology of visceral pain: molecular mechanisms and therapeutic implications: III, visceral afferent pathways: a source of new therapeutic targets for abdominal pain. Am J Physiol 2000; 278: G670-6
180. Fiorucci S, Distrutti E. Role of PAR2 in pain and inflammation. Trends Pharmacol Sci 2002; 23: 153-5